{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:33:29Z","timestamp":1793406809412,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40265-017-0725-1","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T04:30:28Z","timestamp":1489638628000},"page":"615-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy"],"prefix":"10.1007","volume":"77","author":[{"given":"Darren","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3227","authenticated-orcid":false,"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"2","key":"725_CR1","doi-asserted-by":"publisher","first-page":"e0117874","DOI":"10.1371\/journal.pone.0117874","volume":"10","author":"H \u00d6zt\u00fcrk","year":"2015","unstructured":"\u00d6zt\u00fcrk H, Ozkirimli E, \u00d6zg\u00fcr A. Classification of Beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One. 2015;10(2):e0117874.","journal-title":"PLoS One"},{"issue":"3","key":"725_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"725_CR3","doi-asserted-by":"crossref","unstructured":"Bonomo RA. Beta-Lactamases: a focus on current challenges. Cold Spring Harb Perspect Med. 2017;7(1):a025239.","DOI":"10.1101\/cshperspect.a025239"},{"issue":"4","key":"725_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA. New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835\u201346.","journal-title":"Antimicrob Agents Chemother"},{"key":"725_CR5","doi-asserted-by":"crossref","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016;1\u201310.","DOI":"10.1080\/21505594.2016.1222343"},{"key":"725_CR6","doi-asserted-by":"crossref","unstructured":"Wong D, Spellberg B. Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant enterobacteriaceae. Virulence. 2016;1\u20138.","DOI":"10.1080\/21505594.2016.1188234"},{"issue":"12","key":"725_CR7","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1128\/AAC.00568-10","volume":"54","author":"T Stachyra","year":"2010","unstructured":"Stachyra T, P\u00e9chereau MC, Bruneau JM, Claudon M, Fr\u00e8re JM, Miossec C, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"725_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagac\u00e9-Wiens PR, et al. Ceftazidime\u2013avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination. Drugs. 2013;73(2):159\u201377.","journal-title":"Drugs."},{"issue":"2","key":"725_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234\u201341.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"725_CR10","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BL de Jonge","year":"2016","unstructured":"de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime\u2013avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012\u20132014). Antimicrob Agents Chemother. 2016;60(5):3163\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"725_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.00756-10","volume":"55","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"725_CR12","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1128\/AAC.04406-14","volume":"59","author":"KM Papp-Wallace","year":"2015","unstructured":"Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother. 2015;59(7):3710\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"725_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615\u20138.","journal-title":"Clin Infect Dis."},{"key":"725_CR14","doi-asserted-by":"crossref","unstructured":"Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime\u2013avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3). pii: e02097-16.","DOI":"10.1128\/AAC.02097-16"},{"key":"725_CR15","doi-asserted-by":"crossref","unstructured":"Sader HS, Huband MD, Castanheira M, Flamm RK. Antimicrobial susceptibility of Pseudomonas aeruginosa: results from four years (2012\u20132015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States. Antimicrob Agents Chemother. 2017;61(3). pii: e02252-16.","DOI":"10.1128\/AAC.02252-16"},{"issue":"7","key":"725_CR16","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1128\/AAC.01682-10","volume":"55","author":"DM Citron","year":"2011","unstructured":"Citron DM, Tyrrell KL, Merriam V, Goldstein EJ. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55(7):3616\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"725_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jcph.793","volume":"57","author":"H Merdjan","year":"2017","unstructured":"Merdjan H, Tarral A, Das S, Li J. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211\u20138.","journal-title":"J Clin Pharmacol."},{"issue":"10","key":"725_CR18","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","volume":"70","author":"DP Nicolau","year":"2015","unstructured":"Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70(10):2862\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"725_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","volume":"28","author":"JA Vazquez","year":"2012","unstructured":"Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921\u201331.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"725_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","volume":"68","author":"C Lucasti","year":"2013","unstructured":"Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68(5):1183\u201392.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"725_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016;63(6):754\u201362.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"725_CR22","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime\u2013avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380\u20139.","journal-title":"Clin Infect Dis"},{"key":"725_CR23","unstructured":"Food and Drug Administration. Briefing Package NDA 206494 ceftazidime\u2013avibactam. 2014; pp. 1\u201355."},{"issue":"6","key":"725_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime\u2013avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373.","journal-title":"Lancet Infect Dis."},{"issue":"Supplement 1","key":"725_CR25","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/ofid\/ofw172.1595","volume":"3","author":"M King","year":"2016","unstructured":"King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Outcomes with ceftazidime\/avibactam in patients with carbapenem-resistant enterobacteriaceae (CRE) infections: a multi-center study. Open Forum Infect Dis. 2016;3(Supplement 1):2047.","journal-title":"Open Forum Infect Dis."},{"issue":"9","key":"725_CR26","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"SJ Hecker","year":"2015","unstructured":"Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682\u201392.","journal-title":"J Med Chem"},{"issue":"9","key":"725_CR27","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","volume":"60","author":"M Castanheira","year":"2016","unstructured":"Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"725_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/jac\/dkt118","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2013;68(8):1825\u201331.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"725_CR29","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, et al. Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"725_CR30","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/AAC.02418-12","volume":"57","author":"EJ Goldstein","year":"2013","unstructured":"Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother. 2013;57(6):2620\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"725_CR31","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1128\/AAC.01713-15","volume":"59","author":"E Wenzler","year":"2015","unstructured":"Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59(12):7232\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"725_CR32","doi-asserted-by":"crossref","unstructured":"Griffith D, Loutit J, Morgan E, Durso S, Dudley M. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in healthy adult subjects. 24th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain; 2014.","DOI":"10.1093\/ofid\/ofu052.267"},{"key":"725_CR33","doi-asserted-by":"crossref","unstructured":"Meanwell C, Loutit J, Dudley M. TANGO 1 Phase 3 trial results; conference call, PDF; 2016 June 27.","DOI":"10.1093\/ofid\/ofw195.07"},{"key":"725_CR34","unstructured":"BusinessWire. The Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE. In: Visioli C, editor.: The Medicines Company; 2016. http:\/\/www.themedicinescompany.com\/investors\/news\/medicines-company-announces-positive-top-line-results-phase-3-tango-1-clinical-trial. Accessed 2 Jan 2017."},{"issue":"3","key":"725_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bmcl.2013.12.101","volume":"24","author":"TA Blizzard","year":"2014","unstructured":"Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, et al. Discovery of MK-7655, a \u03b2-lactamase inhibitor for combination with Primaxin\u00ae. Bioorg Med Chem Lett. 2014;24(3):780\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"725_CR36","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1128\/AAC.00830-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"725_CR37","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1128\/AAC.05927-11","volume":"56","author":"EB Hirsch","year":"2012","unstructured":"Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56(7):3753\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"725_CR38","first-page":"2286","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"725_CR39","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/AAC.36.9.2046","volume":"36","author":"DM Livermore","year":"1992","unstructured":"Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992;36(9):2046\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"725_CR40","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1128\/AAC.01125-16","volume":"60","author":"DR Snydman","year":"2016","unstructured":"Snydman DR, Jacobus NV, McDermott L. In vitro evaluation of the activity of imipenem\/relebactam (imipenem\/mk-7655) against 451 recent clinical isolates of bacteroides group and related species. Antimicrob Agents Chemother. 2016;60(10):6393\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"725_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1128\/AAC.03706-14","volume":"59","author":"E Mavridou","year":"2015","unstructured":"Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW. Pharmacodynamics of imipenem in combination with \u03b2-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother. 2015;59(2):790\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"725_CR42","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, et al. Phase 2, dose-ranging study of relebactam with imipenem\/cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234\u201343.","journal-title":"Antimicrob Agents Chemother."},{"key":"725_CR43","unstructured":"Eisele P, Consalvo R. Results of phase 2 study of Merck\u2019s Investigational beta-lactamase inhibitor relebactam in combination with imipenem\/cilastatin presented at ASM microbe. June 20 2016. http:\/\/investors.merck.com\/investors\/financial-news\/press-release-details\/2016\/Results-of-Phase-2-Study-of-Mercks-Investigational-Beta-Lactamase-Inhibitor-Relebactam-in-Combination-with-ImipenemCilastatin-Presented-at-ASM-Microbe\/default.aspx."},{"key":"725_CR44","unstructured":"Li D, McConnell I. Results of phase 2 study of Merck\u2019s investigational beta-lactamase inhibitor relebactam. In: Presented at ICAAC\/ICC 2015; 2015 http:\/\/www.mercknewsroom.com\/news-release\/research-and-development-news\/results-phase-2-study-mercks-investigational-beta-lactama."},{"issue":"2","key":"725_CR45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.43.2.424","volume":"43","author":"T K\u00f6hler","year":"1999","unstructured":"K\u00f6hler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43(2):424\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"725_CR46","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1128\/AAC.00574-09","volume":"53","author":"JM Rodr\u00edguez-Mart\u00ednez","year":"2009","unstructured":"Rodr\u00edguez-Mart\u00ednez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"725_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijmm.2011.10.001","volume":"302","author":"H Li","year":"2012","unstructured":"Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol. 2012;302(2):63\u20138.","journal-title":"Int J Med Microbiol"},{"issue":"6","key":"725_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cmi.2016.01.023","volume":"22","author":"C Hauck","year":"2016","unstructured":"Hauck C, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect. 2016;22(6):513\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"725_CR49","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/cid\/ciw398","volume":"63","author":"SL Aitken","year":"2016","unstructured":"Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, et al. High rates of nonsusceptibility to ceftazidime\u2013avibactam and identification of new delhi metallo-\u03b2-lactamase production in enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis. 2016;63(7):954\u20138.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"725_CR50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.diagmicrobio.2013.03.019","volume":"76","author":"EJ Goldstein","year":"2013","unstructured":"Goldstein EJ, Citron DM, Merriam CV, Tyrrell KL. Comparative in vitro activity of ceftaroline, ceftaroline\u2013avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn Microbiol Infect Dis. 2013;76(3):347\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"725_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1128\/AAC.01358-13","volume":"58","author":"BJ Werth","year":"2014","unstructured":"Werth BJ, Rybak MJ. Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(1):559\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"725_CR52","doi-asserted-by":"crossref","unstructured":"Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, et al. Can ceftazidime\/avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02243-16.","DOI":"10.1128\/AAC.02243-16"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-017-0725-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:06:23Z","timestamp":1744715183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-017-0725-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0725-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"assertion":[{"value":"16 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"DvD was supported by R21AI114508-1 from the National Institute of Allergy and Infectious Diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No potential conflicts D.W.Potential conflicts of interest: D.v.D. Actavis, Allergan, Achaogen, Shionogi, Tetraphase, Sanofi-Pasteur, MedImmune, Astellas, Advisory Board. Steris Inc., Research funding. Scynexis Research funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}